Seattle Genetics to Present at Credit Suisse Healthcare Conference
<0> Seattle Genetics, Inc.Peggy Pinkston, 425-527-4160 </0>
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the upcoming Credit Suisse 2012 Healthcare Conference in Phoenix, Arizona. The presentation is scheduled for Thursday, November 15, at 2:30 p.m. Mountain time. It will be webcast live and available for replay from Seattle Genetics’ website at in the section.
Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The U.S. Food and Drug Administration granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage antibody-drug conjugate (ADC) programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at .